Skip to main content

Advertisement

SpringerLink
Log in

Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

To examine influences on the receptor status of a local cohort of patients with recurrent breast cancer after primary diagnosis of hormone receptor positive breast cancer.

Methods

We retrospectively analyzed 2078 female patients with primary hormone receptor positive breast cancer treated at the university hospital of Wuerzburg between 2000 and 2013. Main focus was on discordance in receptor status in recurrent disease.

Results

196 patients with the primary diagnosis of hormone receptor positive breast cancer developed recurrent disease. 29.1% of patients revealed discordance in estrogen receptor (ER), progesterone receptor (PgR) or HER2 receptor (ER+ to −: 33.3%; PgR+ to −: 59.6%; HER2+ to −: 8.8%; HER2− to +: 17.5%). Aggressive tumor biology such as low grading or involvement of axillary lymph nodes showed increased risk of receptor conversion in relapse. Premenopausal patients with adjuvant application of tamoxifen and the application of chemotherapy had a significantly lower risk for the development of ER negative recurrent disease. Receptor changes to ER and PgR negativity in recurrent disease showed a trend to worse overall survival (OS).

Conclusions

Histological analysis of recurrent disease is indispensable, since one-third of patients with hormone receptor positive breast cancer develop change in the receptor status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Robert-Koch-Institute R. Bericht zum Krebsgeschehen in Deutschland 2016. 2016. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_download.pdf?__blob=publicationFile

  2. World Health Organization. Breast cancer-estimated incidence, mortality and prevalence worldwide in 2012. 2012 Available from: https://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf

  3. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 15:153–179

    PubMed  PubMed Central  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

    Article  CAS  Google Scholar 

  5. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Moulder S (2010) Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond). 6(6):821–830

    Article  CAS  PubMed  Google Scholar 

  7. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30(21):2601–2608

    Article  PubMed  Google Scholar 

  8. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M et al (2013) Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 24(1):101–108

    Article  CAS  PubMed  Google Scholar 

  9. Schrijver W, Schuurman K, van Rossum A, Dutch Distant Breast CancerMetastases C, Peeters T, Ter Hoeve N et al (2017) Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget 8(33):55550–55561

    Article  PubMed  PubMed Central  Google Scholar 

  10. Timmer M, Werner JM, Rohn G, Ortmann M, Blau T, Cramer C et al (2017) Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res 37(9):4859–4865

    CAS  PubMed  Google Scholar 

  11. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K et al (2009) Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 101(9):1529–1536

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK et al (2015) Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15(2):153–160

    Article  CAS  PubMed  Google Scholar 

  13. Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C et al (2013) Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 18(6):667–674

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bogina G, Bortesi L, Marconi M, Venturini M, Lunardi G, Coati F et al (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459(1):1–10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang YF, Liao YY, Yang M, Peng NF, Xie SR, Xie YF (2014) Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol 31(10):214

    Article  CAS  PubMed  Google Scholar 

  16. Turner NH, Di Leo A (2013) HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev 39(8):947–957

    Article  CAS  PubMed  Google Scholar 

  17. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302–312

    Article  CAS  PubMed  Google Scholar 

  18. Karthik GM, Rantalainen M, Stalhammar G, Lovrot J, Ullah I, Alkodsi A et al (2017) Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. BMC Cancer. 17(1):802

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. German Cancer Society (DKG), German Society of Gynecology and Obstetrics (DGGG) (2017) Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie http://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Mammakarzinom_Langversion_4.0.pdf

Download references

Acknowledgements

We would like to thank Professor Dr. Manfred Wischnewsky, Department of Mathematics and Computer Science, University of Bremen for statistical advice.

Funding

TN. Stueber was funded by the Interdisciplinary Center for Clinical Research at the University hospital of Wuerzburg and the Else Kroener-Fresenius-Stiftung

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, University Hospital Wuerzburg, Josef-Schneider-Str. 4, 97080, Wuerzburg, Germany

    Tanja Nadine Stueber, Achim Woeckel & Sebastian Haeusler

  2. Department of Obstetrics and Gynecology, Charité, Campus Virchow, University Hospital Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

    Claire Rachel Weiss

  3. Department of Obstetrics and Gynecology, University of Regensburg, Hospital of the Order of St. John of God Regensburg-St. Hedwig Clinic, Steinmetzstraße 1-3, 93049, Regensburg, Germany

    Sebastian Haeusler

Authors
  1. Tanja Nadine Stueber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire Rachel Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Achim Woeckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sebastian Haeusler
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TNS: conceptualization, investigation, software, supervision, visualization, writing of original draft. CRW: data curation, software, formal analysis, methodology, writing parts of the original draft and editing. AW: conceptualization, funding acquisition, project administration, editing of the manuscript. SH: conceptualization, investigation, project administration, supervision, editing the manuscript. All authors contributed to the final manuscript including interpretation of data and review of the literature.

Corresponding author

Correspondence to Tanja Nadine Stueber.

Ethics declarations

Conflict of interest

TN. Stueber: received fees from Roche Pharma; CR Weiss: none; A. Woeckel: received fees from Roche, Pfizer, Novartis, Amgen, Celgene, Eisai; S. Haeusler: received fees from Novartis and Roche Pharma.

Ethical approval

As the study consisted of the retrospective analysis of anonymized data according to the local ethics committee a special approval is generally not required.

Additional information

Tanja Nadine Stueber and Claire Rachel Weiss shared first authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stueber, T.N., Weiss, C.R., Woeckel, A. et al. Influences of adjuvant treatments in hormone receptor positive breast cancer on receptor conversion in recurrent breast cancer. Arch Gynecol Obstet 299, 533–541 (2019). https://doi.org/10.1007/s00404-018-4954-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-018-4954-7

Keywords

Search

Navigation